This cost-utility analysis compares the cost-effectiveness of salmeterol, fluticasone propionate, combination salmeterolfluticasone, and no maintenance therapy in chronic obstructive pulmonary disease ...

BOSTON, MA - JUNE 6: Steven Pearson, President of the Institute for Clinical and Economic Review (ICER), talks with chief medical officer David Rind during a meeting at their offices in Boston on June ...

Several new treatment combinations have been approved in metastatic renal cell carcinoma (mRCC). To determine the optimal therapy on the basis of cost and health outcomes, we performed a ...

We constructed decision-analytic models to analyze three strategies (no screening, universal screening, and selective screening based on use of an HBV infection risk tool) for hypothetic cohorts of ...

Demand for humanitarian assistance is growing and existing financial resources are inadequate to address all areas of need. As stewards of limited funds, we have a responsibility to make the most ...

This article estimates the comprehensive value of direct-acting antivirals for the treatment of hepatitis C virus using a generalized cost-effectiveness analysis. Objectives: To estimate the ...

As an epidemiologist and physician, I’ve long been concerned about how health interventions for marginalized communities are evaluated. A new study explores that concern and offers some solutions for ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Efanesoctocog alfa prophylaxis is conventionally cost-ineffective compared with standard factor VIII ...

Vertex Pharmaceuticals’ drug, Trikafta, which was approved as a breakthrough treatment for cystic fibrosis last year, needs to be 73 percent cheaper to be cost-effective, an analysis found. The ...

Vaccines may be scientific wonders, but their value ultimately rests on how well we can get shots into people’s arms. This is an obvious but still overlooked truth that the COVID-19 pandemic has ...